Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis.

Fan Bai, Wen Zheng, Yan Dong, Juan Wang, Malgorzata A Garstka, Ruilian Li, Jingang An, Huiqun Ma
Author Information
  1. Fan Bai: The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  2. Wen Zheng: The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  3. Yan Dong: The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  4. Juan Wang: The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  5. Malgorzata A Garstka: The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  6. Ruilian Li: The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  7. Jingang An: The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  8. Huiqun Ma: The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Abstract

PURPOSE: To evaluate the association of serum levels of adipokines and cytokines with psoriasis.
MATERIALS AND METHODS: A comprehensive literature search was performed in PubMed, ScienceDirect and Web of Science for the available relevant studies published before December 1, 2016. Differences in serum marker levels between patients and controls were pooled as standardized mean differences (SMDs) with 95% confidence interval to combine the effect estimations. We also conducted stratified analysis, meta-regression analysis and sensitivity analysis.
RESULTS: Sixty-three studies containing 2876 psoriasis patients and 2237 healthy controls were included in this meta-analysis. The pooled serum levels of TNF-α, IFN-γ, IL-2, IL-6, IL-8, IL-18, IL-22, chemerin, lipocalin-2, resistin, sE-selectin, fibrinogen and C3 were higher in psoriasis patients compared with healthy controls (all < 0.05). In contrast, adiponectin levels were lower. Serum levels of IL-1β, IL-4, IL-10, IL-12, IL-17, IL-21, IL-23, visfatin and omentin were not significantly different between psoriasis patients and controls (all > 0.05). However, increased serum levels of IL-17 correlated with psoriasis in men. For other biomarkers, age, gender and psoriasis area and severity index did not explain the differences in effect size between the studies.
CONCLUSIONS: Serum levels of TNF-α, IFN-γ, IL-2, IL-6, IL-8, IL-18, IL-22, chemerin, lipocalin-2, resistin, sE-selectin, fibrinogen, complement 3, and adiponectin correlate with psoriasis and can be used as potential biomarkers for psoriasis and response to the treatment. Future studies are needed to identify additional players involved in the pathogenesis of psoriasis and to fully decipher the underlying mechanism.

Keywords

References

  1. J Clin Lab Anal. 2016 Mar;30(2):165-8 [PMID: 25545917]
  2. Horm Mol Biol Clin Investig. 2014 Apr;18(1):37-45 [PMID: 25389999]
  3. J Int Med Res. 2014 Apr;42(2):386-94 [PMID: 24445696]
  4. Diabetes Res Clin Pract. 2010 Apr;88(1):29-33 [PMID: 20129687]
  5. J Clin Endocrinol Metab. 2010 May;95(5):2476-85 [PMID: 20237162]
  6. J Cutan Med Surg. 2015 Nov-Dec;19(6):555-60 [PMID: 25917082]
  7. J Exp Med. 2003 Oct 6;198(7):977-85 [PMID: 14530373]
  8. J Eur Acad Dermatol Venereol. 2010 Dec;24(12):1386-94 [PMID: 20337818]
  9. Clin Exp Dermatol. 2000 Nov;25(8):643-7 [PMID: 11167981]
  10. Postepy Dermatol Alergol. 2015 Apr;32(2):101-6 [PMID: 26015779]
  11. Biochem Biophys Res Commun. 2011 May 6;408(2):339-43 [PMID: 21514279]
  12. Exp Dermatol. 2011 Oct;20(10):845-7 [PMID: 21732985]
  13. J Immunol Res. 2014;2014:467541 [PMID: 25759829]
  14. Arch Dermatol Res. 2014 Apr;306(3):239-45 [PMID: 24052155]
  15. Clin Immunol. 2010 Apr;135(1):108-17 [PMID: 20006553]
  16. Immunol Res. 2013 Jul;56(2-3):382-9 [PMID: 23572429]
  17. Br J Dermatol. 2004 May;150(5):917-28 [PMID: 15149504]
  18. Cardiovasc Res. 2008 May 1;78(2):356-65 [PMID: 18093986]
  19. Biometrics. 1994 Dec;50(4):1088-101 [PMID: 7786990]
  20. Dis Markers. 2014;2014:541709 [PMID: 24803721]
  21. Exp Dermatol. 2011 Feb;20(2):81-7 [PMID: 21255085]
  22. Chin J Integr Med. 2015 Feb;21(2):108-14 [PMID: 25523599]
  23. Dis Markers. 2013;35(6):625-31 [PMID: 24288431]
  24. Br J Dermatol. 2008 Aug;159(2):342-50 [PMID: 18547319]
  25. Br J Dermatol. 1996 Jan;134(1):17-21 [PMID: 8745880]
  26. Br J Dermatol. 2013 Apr;168(4):749-55 [PMID: 23110708]
  27. Circulation. 2003 Aug 12;108(6):736-40 [PMID: 12874180]
  28. Int J Dermatol. 2015 Jul;54(7):839-45 [PMID: 25877149]
  29. BMJ. 1998 Feb 7;316(7129):471 [PMID: 9492690]
  30. Semin Immunopathol. 2016 Jan;38(1):11-27 [PMID: 26573299]
  31. Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1253-61 [PMID: 16531507]
  32. Acta Dermatovenerol Croat. 2016 Apr;24(1):13-9 [PMID: 27149125]
  33. Br J Dermatol. 2010 Nov;163(5):1085-9 [PMID: 20716221]
  34. Diabetes. 2007 Jun;56(6):1655-61 [PMID: 17329619]
  35. J Eur Acad Dermatol Venereol. 2017 Feb;31(2):205-212 [PMID: 27573025]
  36. Hum Immunol. 2010 Dec;71(12):1161-71 [PMID: 20849904]
  37. Tohoku J Exp Med. 2012;228(4):325-32 [PMID: 23132229]
  38. J Am Coll Cardiol. 2011 Jan 4;57(1):99-109 [PMID: 21185508]
  39. Acta Derm Venereol. 2008;88(4):337-40 [PMID: 18709301]
  40. J Eur Acad Dermatol Venereol. 2011 Nov;25(11):1328-33 [PMID: 21349112]
  41. Inflammation. 1998 Oct;22(5):533-43 [PMID: 9793799]
  42. J Cell Mol Med. 2015 Jul;19(7):1637-45 [PMID: 25702801]
  43. Cytokine. 2013 Mar;61(3):704-12 [PMID: 23410503]
  44. Int J Med Sci. 2010 Aug 19;7(5):284-9 [PMID: 20827428]
  45. Ann Dermatol. 2015 Dec;27(6):738-43 [PMID: 26719644]
  46. Mediators Inflamm. 2005 Oct 24;2005(5):273-9 [PMID: 16258194]
  47. J Dermatol Sci. 2009 Jul;55(1):62-3 [PMID: 19395243]
  48. Ann N Y Acad Sci. 1995 Jul 21;762:432-4 [PMID: 7668549]
  49. J Eur Acad Dermatol Venereol. 2003 Jan;17(1):42-6 [PMID: 12602967]
  50. Ann Rheum Dis. 1981 Feb;40(1):66-9 [PMID: 6970552]
  51. Br J Dermatol. 2012 Oct;167(4):762-7 [PMID: 22564054]
  52. Mediators Inflamm. 2003 Oct;12(5):309-13 [PMID: 14760939]
  53. J Invest Dermatol. 2006 Feb;126(2):510-2 [PMID: 16374475]
  54. Prostate. 2015 Jun 15;75(9):957-68 [PMID: 25728945]
  55. J Dermatol Sci. 2016 Feb;81(2):93-100 [PMID: 26614745]
  56. J Clin Lab Anal. 2016 Sep;30(5):768-75 [PMID: 27061381]
  57. Diabetes. 2009 Dec;58(12):2731-40 [PMID: 19720798]
  58. Clin Chim Acta. 2008 Aug;394(1-2):7-21 [PMID: 18445484]
  59. Cytokine Growth Factor Rev. 2011 Oct-Dec;22(5-6):331-8 [PMID: 22119008]
  60. Cytokine. 2016 Jan;77:10-3 [PMID: 26499979]
  61. Clin Chim Acta. 2003 Jun;332(1-2):23-30 [PMID: 12763276]
  62. J Biol Chem. 2007 Sep 21;282(38):28175-88 [PMID: 17635925]
  63. Arch Dermatol Res. 2013 Mar;305(2):105-12 [PMID: 23242471]
  64. J Eur Acad Dermatol Venereol. 2015 Jan;29(1):69-76 [PMID: 24665910]
  65. Br J Dermatol. 2013 Aug;169(2):266-82 [PMID: 23550658]
  66. Br J Dermatol. 2011 Mar;164(3):667-70 [PMID: 21062267]
  67. Arch Dermatol Res. 2011 Aug;303(6):451-5 [PMID: 21681565]
  68. Clin Chim Acta. 2012 Oct 9;413(19-20):1652-6 [PMID: 22609260]
  69. Glycobiology. 2001 Jan;11(1):65-73 [PMID: 11181563]
  70. Allergy. 2017 Nov;72 (11):1694-1703 [PMID: 28378334]
  71. Int J Immunopathol Pharmacol. 2010 Oct-Dec;23(4):1195-202 [PMID: 21244768]
  72. Eur J Dermatol. 2012 May-Jun;22(3):337-44 [PMID: 22503884]
  73. Nat Commun. 2015 Jul 15;6:7687 [PMID: 26173479]
  74. Blood. 1994 Feb 1;83(3):799-807 [PMID: 8298140]
  75. Br J Dermatol. 2017 Mar;176(3):563 [PMID: 28300302]
  76. J Immunol. 2007 Feb 1;178(3):1748-58 [PMID: 17237424]
  77. Arch Dermatol Res. 2015 Jul;307(5):413-24 [PMID: 25648959]
  78. G Ital Dermatol Venereol. 2014 Apr;149(2):167-75 [PMID: 24819636]
  79. J Immunol Res. 2016;2016:5380792 [PMID: 28097156]
  80. J Invest Dermatol. 2010 Jul;130(7):1785-96 [PMID: 20445552]
  81. J Clin Invest. 2008 Apr;118(4):1468-78 [PMID: 18317594]
  82. Int Arch Allergy Immunol. 1996 Jul;110(3):199-206 [PMID: 8688665]
  83. Biochem Biophys Res Commun. 2010 Jan 22;391(4):1762-8 [PMID: 20044979]
  84. Br J Dermatol. 2013 Nov;169(5):1066-70 [PMID: 23889284]
  85. Rev Endocr Metab Disord. 2016 Sep;17 (3):305-317 [PMID: 27554109]
  86. Immunol Lett. 2003 May 1;86(3):277-80 [PMID: 12706531]
  87. Arch Dermatol Res. 2012 Aug;304(6):465-9 [PMID: 22426986]
  88. Clin Chim Acta. 2003 Feb;328(1-2):71-82 [PMID: 12559600]
  89. Int J Dermatol. 2012 Apr;51(4):389-95; quiz 395-8 [PMID: 22435425]
  90. Endocrinology. 2010 Jun;151(6):2590-602 [PMID: 20363880]
  91. Circ J. 2010 Feb;74(2):213-20 [PMID: 20065609]
  92. J Eur Acad Dermatol Venereol. 2016 Nov;30(11):1876-1885 [PMID: 27230733]
  93. Endocrinology. 2007 Oct;148(10):4687-94 [PMID: 17640997]
  94. Am J Cardiol. 2016 Aug 15;118(4):603-9 [PMID: 27392508]
  95. Ann Dermatol. 2016 Feb;28(1):74-9 [PMID: 26848221]
  96. Exp Dermatol. 2012 Jan;21(1):43-7 [PMID: 22151390]
  97. J Biol Chem. 1996 May 3;271(18):10697-703 [PMID: 8631877]
  98. Clin Exp Dermatol. 1999 Jan;24(1):33-6 [PMID: 10233646]
  99. Nature. 2004 Dec 16;432(7019):917-21 [PMID: 15531878]
  100. N Engl J Med. 2005 May 5;352(18):1899-912 [PMID: 15872205]
  101. Clin Exp Dermatol. 2010 Aug;35(6):645-9 [PMID: 19843085]
  102. J Dermatol. 2017 Apr;44(4):363-369 [PMID: 27774694]
  103. Acta Derm Venereol. 2011 Sep;91(5):516-20 [PMID: 21547343]
  104. Clin Exp Dermatol. 2012 Apr;37(3):296-9 [PMID: 22300286]
  105. Endocrinology. 2004 May;145(5):2273-82 [PMID: 14726444]
  106. Int J Biol Sci. 2011 Jan 18;7(1):74-86 [PMID: 21278918]
  107. Biochem Biophys Res Commun. 2012 Aug 31;425(3):556-9 [PMID: 22925673]
  108. J Int Med Res. 2010 Jul-Aug;38(4):1507-12 [PMID: 20926025]
  109. J Tradit Chin Med. 2005 Dec;25(4):292-5 [PMID: 16447674]
  110. J Rheumatol. 2011 Mar;38(3):567-71 [PMID: 21362790]
  111. J Invest Dermatol. 2016 Jul;136(7):1418-1428 [PMID: 26979478]
  112. Infect Immun. 2014 Mar;82(3):1030-5 [PMID: 24343647]
  113. Br J Dermatol. 2012 Jul;167(1):191-3 [PMID: 22356196]
  114. Acta Derm Venereol. 1999 Mar;79(2):132-5 [PMID: 10228632]
  115. Physiol Res. 2006;55(6):699-706 [PMID: 16497101]
  116. Regul Pept. 2009 Apr 10;154(1-3):102-6 [PMID: 19233230]
  117. J Dermatol. 2011 May;38(5):442-6 [PMID: 21352285]
  118. Acta Derm Venereol. 1999 Nov;79(6):462-4 [PMID: 10598762]
  119. Science. 1995 Jul 28;269(5223):546-9 [PMID: 7624778]
  120. Arch Dermatol Res. 2014 Sep;306(7):653-60 [PMID: 24848273]
  121. J Dermatol Sci. 2017 Jul;87(1):36-49 [PMID: 28431948]

Word Cloud

Created with Highcharts 10.0.0psoriasislevelsserumstudiespatientscontrolsanalysismeta-analysisSerumadipokinescytokinespooleddifferenceseffecthealthyTNF-αIFN-γIL-2IL-6IL-8IL-18IL-22chemerinlipocalin-2resistinsE-selectinfibrinogen005adiponectinIL-17biomarkersPURPOSE:evaluateassociationMATERIALSANDMETHODS:comprehensiveliteraturesearchperformedPubMedScienceDirectWebScienceavailablerelevantpublishedDecember12016DifferencesmarkerstandardizedmeanSMDs95%confidenceintervalcombineestimationsalsoconductedstratifiedmeta-regressionsensitivityRESULTS:Sixty-threecontaining28762237includedC3highercompared<contrastlowerIL-1βIL-4IL-10IL-12IL-21IL-23visfatinomentinsignificantlydifferent>HoweverincreasedcorrelatedmenagegenderareaseverityindexexplainsizeCONCLUSIONS:complement3correlatecanusedpotentialresponsetreatmentFutureneededidentifyadditionalplayersinvolvedpathogenesisfullydecipherunderlyingmechanismpatients:systematicreviewadipokinecytokine

Similar Articles

Cited By